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Key Points
• The study establishes a reli-
able method to quantify differ-
entiating mouse erythroblasts
and to monitor terminal mouse
erythropoiesis in vivo.
• Quantitative analysis of eryth-
ropoiesis of thalassemia mice
revealed stage-specific
changes in terminal erythroid
differentiation.
Terminal erythroid differentiation is the process during which proerythroblasts differen-
tiate to produce enucleated reticulocytes. Although it is well established that during
murine erythropoiesis in vivo, 1 proerythroblast undergoes 3 mitosis to generate
sequentially 2 basophilic, 4 polychromatic, and 8 orthochromatic erythroblasts, cur-
rently there is no method to quantitatively monitor this highly regulated process. Here
we outline a method that distinguishes each distinct stage of erythroid differentiation in
cells from mouse bone marrow and spleen based on expression levels of TER119, CD44,
and cell size. Quantitative analysis revealed that the ratio of proerythroblasts:basophilic:
polychromatic:orthromatic erythroblasts follows the expected 1:2:4:8 ratio, reflecting
the physiologic progression of terminal erythroid differentiation in normal mice.
Moreover, in 2 stress erythropoiesis mouse models, phlebotomy-induced acute anemia
and chronic hemolytic anemia because of 4.1R deficiency, the ratio of these erythroblast
populations remains the same as that of wild-type bone marrow. In contrast, in anemic
-thalassemia intermedia mice, there is altered progression which is restored to normal
by transferrin treatment which was previously shown to ameliorate the anemic phenotype. The means to quantitate in vivo murine
erythropoiesis using our approach will probably have broad application in the study of altered erythropoiesis in various red cell
disorders. (Blood. 2013;121(8):e43-e49)
Introduction
Erythropoiesis is a process during which multipotent hematopoietic
stem cells (HSCs) proliferate, differentiate, and ultimately produce
enucleate reticulocytes. Although erythropoiesis is continuous and
dynamic, it is broadly distinguished to occur in 2 phases: erythroid
progenitor proliferation and terminal erythroid differentiation.
Early stage erythropoiesis refers to the process by which HSCs
proliferate, differentiate, and generate erythroid progenitors: burst
forming unit-erythroid (BFU-E) and colony forming unit-erythroid
(CFU-E). BFU-E and CFU-E are traditionally defined by colony
assays.1-4 Abnormal BFU-E or CFU-E colony forming ability
reflects either perturbed commitment of HSCs to the erythroid
lineage or intrinsic defects in BFU-E or CFU-E.
Terminal erythroid differentiation begins at the morphologically
recognizable proerythroblast stage. Murine proerythroblasts un-
dergo 3 mitoses to generate sequentially basophilic, polychromatic,
and orthochromatic erythroblasts. Orthochromatic erythroblasts
expel their nuclei to produce reticulocytes. Notable cellular changes
occur during terminal erythroid differentiation, including decreases
in cell size, chromatin condensation, and hemoglobinization.
Under physiologic conditions, a single proerythroblast (Pro) will
generate 2 basophilic erythroblasts (Baso), and the 2 basophilic
erythroblasts produce 4 polychromatic erythroblasts (Poly). Fi-
nally, the 4 polychromatic erythroblasts generate 8 orthochromatic
erythroblasts (Ortho). Thus, it is expected that during normal
murine terminal erythroid differentiation, the ratio of Pro:Baso:Poly:
Ortho follows a 1:2:4:8 pattern.
To understand the molecular basis of abnormal erythropoiesis
leading to many inherited and acquired anemias, there is a critical
need for a method that quantifies the population of cells at each
distinct stage during in vivo terminal differentiation. To address
this issue, more than a decade ago, Socolovsky et al introduced a
flow cytometry-based assay using TER119 and CD71 as surface
markers to distinguish murine erythroblasts at different differentia-
tion stages.5 The method was subsequently improved by adding
forward scatter (which reflects the cell size) as an additional
marker.6 These methods have been extensively used to study
erythropoiesis in a variety of murine models of disordered erythro-
poiesis. However, these methods fail to recapitulate the physiologic
progression of normal murine terminal erythroid differentiation in
a ratio of Pro:Baso:Poly:Ortho of 1:2:4:8. Indeed, in various
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published studies hugely variable results were obtained.7-12 To
better resolve distinct stages of murine erythroblasts, we recently
examined the expression of individual membrane proteins during
murine erythropoiesis and documented that the adhesion molecule
CD44 exhibited a progressive and dramatic decrease from Pro to
reticulocytes.13 Based on the changes in expression levels of GPA,
CD44 and cell size, we developed a cell-sorting strategy to isolate
significantly more homogeneous populations of erythroblasts at
each stage of terminal differentiation, than had been achieved in
earlier work.13 However, this technique was not optimized to
reproducibly quantify the normal physiologic ratio of Pro:Baso:Poly:
Ortho of 1:2:4:8 or identify potential pathology in terminal
erythroid differentiation in inherited and acquired red cell disorders.
Here we outline a method that accurately captures the physi-
ologic progression of terminal differentiation in murine bone
marrow and spleen. We observe that the ratio of Pro:Baso:Poly:
Ortho in mouse bone marrow follows the 1:2:4:8 pattern, demon-
strating the expected doubling of cell number with each successive
mitosis. To validate this methodology as a tool for study of
erythropoiesis in red cell disorders, we analyzed the progression of
erythropoiesis in 3 anemic mouse models. We observed a normal
progression of erythropoiesis in 2 anemic mouse models:
phlebotomy-induced acute anemia and chronic hemolytic anemia
because of 4.1R deficiency, indicating no stage-specific defects
inhibiting cells from proceeding along the differentiation pathway
in normal numbers. In contrast, -thalassemia intermedia (Hbbth1/th1)
mice demonstrated a disordered progression from Pro to Baso
erythroblasts. Interestingly, transferrin therapy, which restores the
normal erythropoiesis in Hbbth1/th1 mice, corrected the disordered
progression. The innovative method we outlined that enables the
quantification of cells at each stage of differentiation during in vivo
erythropoiesis, should facilitate detailed mechanistic studies to
define stage-specific defects in erythroid maturation in various
inherited and acquired red cell disorders.
Methods
Mice
The 4.1R knockout mice were previously described14 and Hbbth1/th1 mice15
in a mixed genetic background were purchased from Jackson Laboratories.
Both mice lines were backcrossed onto a C57BL/6 background. C57BL/6
(WT) mice were purchased from Jackson Laboratories. All mice were
maintained at the New York Blood Center Animal Facility under specific
pathogen free conditions according to institutional guidelines. Animal
protocols were reviewed and approved by the Institutional Animal Care and
Use Committee. Four to 6-month-old, male WT, 4.1R knockout, and
Hbbth1/th1 mice were used in the studies. WT mice were bled to induce
anemia according to the method previously described.16 Hbbth1/th1 mice
were treated with 10 mg (400 mg/kg/d) of transferrin or PBS via
intraperitoneal injections daily for a total of 20 days; this treatment course
correlated with our previous data obtained after 60 days of injections (data
not shown).17
Antibodies
CD16/CD32 (Fc III/II Receptor), FITC-conjugated anti-Ter119, APC-
conjugated anti-CD44, APC-Cy 7–conjugated anti-CD45, APC-Cy
7–conjugated anti-CD11b, APC-Cy 7–conjugated anti-GR1, and 7AAD
were purchased from BD Bioscience. Anti-transferrin receptor antibody
was from Invitrogen.
Preparation of bone marrow and spleen single-cell
suspensions
For bone marrow single-cell suspension preparation, cells from mice tibia
and femur were flushed with PBS/0.5% BSA/2mM EDTA and the cell
suspension was gently passed through 271⁄2 G needle 3 to 4 times. For
spleen single cell suspension preparation, a whole spleen was placed into a
cell strainer and smashed through the cell strainer into a petri dish. The cell
strainer was rinsed with 5 mL cold PBS/0.5%BSA buffer. The cells were
transferred to a 15-mL conical tube and centrifuged at 300g for 5 minutes.
After centrifugation, the cell pellet was suspended in PBS/0.5% BSA buffer.
Depletion of CD45 cells
A single-cell suspension of bone marrow or spleen was centrifuged at 300g
for 10 minutes, at 4°C. After centrifugation, 107 cells were resuspended in
90 L of buffer, to which 10 L of mouse CD45 MicroBeads (Miltenyi
Biotec) was added. The mixture was incubated for 15 minutes at 4°C, and
after the addition of 1 mL of buffer, centrifuged at 300g for 10 minutes. The
cell pellet was resuspended in 500 L of buffer. The CD45 and CD45
cells were separated by magnetic separation with LS columns according to
the instruction from the manufacture (Miltenyi Biotec). The flow through
fraction (CD45 cells) was collected for further staining.
Staining of CD45 cells and flow cytometric analysis
Cells were suspended in PBS/0.5% BSA buffer at the concentration of
106/80 L and incubated with rat anti–mouse CD16/CD32 (2.5 g/106
cells) for 15 minutes on ice. Samples were subsequently stained with
FITC-conjugated rat anti–mouse TER-119 (0.5 g/106 cells), APC-
conjugated rat anti–mouse CD44 (0.2 g/106 cells), APC-Cy 7–conjugated
anti-CD45 (0.1g/106 cells), APC-Cy 7–conjugated anti-CD11b (0.1g/106
cells), and APC-Cy 7–conjugated anti-GR1(0.1 g/106 cells) on ice for
20 to 30 minutes in the dark. Cells were washed twice with 700 L
PBS/0.5% BSA. Finally, cells were suspended in 100 L PBS/0.5% BSA
and stained with the viability marker 7-AAD (0.25 g/106 cells) on ice for
10 minutes in the dark. After the staining, cells were suspended in 0.4 mL of
PBS/0.5%BSA and analyzed within 1 hour of staining using BD FACSDiva
Version 6.1.2 software on a FACSCanto flow cytometer (Becton Dickin-
son). The instrument settings were as follows: FSC: 319, SSC: 568; voltage
for different fluorescent dyes: FITC:575, PE: 661, APC: 676, APC-Cy 7:
670, 7-AAD: 691. Unstained cells were used as a negative control.
Gating procedure
Using 7AAD as a marker, dead cells were gated out. Among live cells, the
residual leukocytes, monocytes, and granulocytes remaining after CD45
depletion were gated out using APC-Cy7–conjugated CD45, GR1, and
CD11b as markers. CD45GR1CD11b TER119 cells were analyzed in
2 ways: TER119 versus CD44 and CD44 versus FSC. Population I was gated
on the CD44/TER119 plot, which is defined as CD44hiTER119low popula-
tion. All other populations were gated on the CD44/FSC plot. In this plot,
there are 2 very clear clusters which we gated as IV and V. A less clear cluster
below region V was gated as region VI. Similarly, a less well-defined cluster on
the upper-right side of region IV was gated as region III. Finally, the area between
region I and region III was gated as region II.
Fluorescence-activated cell sorting
To isolate erythroblasts at different stages of maturation, 200  106 cells
were suspended in 8 mL PBS/0.5% BSA in a 50-mL tube. Cells were
blocked with rat anti–mouse CD16/CD32 (2.5g /106 cells) for 15 minutes
and subsequently stained with FITC rat anti–mouse TER-119 (0.5 g/106
cells), APC rat anti–mouse CD44 (0.2 g/106 cells), APC-Cy 7–conjugated
anti-CD45(0.1g/106 cells), APC-Cy 7–conjugated anti-CD11b (0.1g/106
cells), and APC-Cy 7–conjugated anti-GR1(0.1 g/106 cells) antibodies,
and then incubated on ice for 30 minutes in the dark. Cells were washed
twice with 40 mL PBS/0.5% BSA buffer and resuspended in 8 mL
PBS/0.5% BSA buffer and stained with the viability marker 7-AAD
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(0.25 g/106 cells) on ice for 10 minutes in the dark. Sorting was performed
on a MOFLO high-speed cell sorter (Beckman-Coulter).
Cytospin preparation
One-hundred milliliters of cell suspension containing 105 sorted cells was
used to prepare cytospin preparations on coated slides, using the Thermo
Scientific Shandon 4 Cytospin. The slides were stained with May-Grunwald
(Sigma-Aldrich MG500) solution for 5 minutes, rinsed in 40mM Tris buffer
(pH 7.2) for 90 seconds, and subsequently stained with 1:10 diluted Giemsa
solution (Sigma-Aldrich GS500) for 15 minutes.
Western blot analysis
Serum samples were separated by sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE) using 10% polyacrylamide gels, and the
proteins were electrophoretically transferred to polyvinylidene difluoride
membrane (Immobilon-P; Millipore). Membranes were blocked for 1 hour
in TBS-T (10mM Tris-HCl, pH 8.0; 150mM NaCl; 0.05% Tween 20)
containing 5% skim milk, followed by 1 hour incubation with anti-
transferrin receptor antibody. Blots were washed and incubated for 1 hour at
room temperature with the secondary antibody (horseradishperoxidase
[HRP]–conjugated). Immunoreactive bands were visualized by the en-
hanced chemiluminescence (ECL) method (Amersham Bioscience) accord-
ing to standard procedures.
Statistical analyses
All data are reported as mean SD. We performed analysis for statistically
significant differences with the student unpaired t test.
Results
Quantitation of in vivo erythropoiesis in murine bone marrow
It is well accepted that during murine terminal erythroid differentia-
tion the proerythroblast undergoes 3 cell divisions to differentiate
sequentially into basophilic, polychromatic, and orthochromatic
erythroblasts. Thus, it is expected that under normal physiologic
conditions 1 proerythroblast would produce 8 orthochromatic
erythroblasts. To develop a method that would accurately reflect the
physiologic progression of in vivo terminal differentiation and
enable the quantitation of the number of cells in the various developmen-
tal stages, we first depleted CD45 cells from single cell suspen-
sions of normal murine bone marrow by magnetic separation. The
CD45 cells were then stained with FITC-conjugated rat anti-
mouse TER119, APC-conjugated rat anti–mouse CD44, APC-Cy
7–conjugated anti-CD45, APC-Cy 7–conjugated anti-CD11b,
APC-Cy 7–conjugated anti-GR1 and the viability marker 7AAD.
The stained cells were analyzed by flow cytometry.
For clarity, the entire procedure for the gating strategy is shown
in Figure 1 and summarized in this section: (1) Figure 1A shows the
plot of FSC versus SSC of all cells in the cell suspension being
analyzed; (2) the live cells (P1) were gated as 7AAD negative cells
(Figure 1B); (3) within the P1 population, cells of erythroid lineage
(P2) were gated as CD45CD11bGR1 cells (Figure 1C); (4) his-
togram of TER119 expression of P2 showed that all P2 cells were
TER119 positive (Figure 1D); (5) plot of CD44 versus TER119 of
the TER119 positive cells revealed a distinct CD44hiTERlow
population (Figure 1E), which was gated as region I (Figure 1F);
and (6) plot of CD44 versus FSC of the TER119 positive cells
revealed 4 naturally occurring cell clusters (Figure 1G), which
were gated as region III, IV, V, and VI, respectively, and the
nonclustered region between region I and region III was gated as
region II (Figure 1H).
The representative images of the sorted populations are shown
in Figure 1I which reveals that region I through region VI are
proerythroblasts, basophilic erythroblasts, polychromatic erythro-
blasts, orthochromatic erythroblasts, reticulocytes, and mature red
cells, respectively. The purity of each population is  90%. As
shown in Figure 1J, the FSC (reflecting the cell size) decreased
progressively from proerythroblasts to orthochromatic erythro-
blasts. Importantly, Figure 1K reveals that proerythroblasts, baso-
philic erythroblasts, polychromatic erythroblasts, and orthochro-
matic erythroblasts account for 2%, 4%, 8.7%, and 17% of the total
TER119 positive cells, respectively, demonstrating the doubling of
the cells on each mitosis. The proportion of cells at each distinct
stage of maturation after normalization based on total nucleated
erythroid cells as 100% is summarized in Table 1. Pro, Baso, Poly,
and Ortho account for 6%, 13%, 28%, and 53% of the total
nucleated erythroblasts, respectively, validating the doubling of
cells from one stage to the next.
Normal progression of terminal erythroid differentiation in the
bone marrow and spleen of anemic mice because of
4.1R-deficiency or after phlebotomy
To validate the use of the methodology as a tool for studying
erythropoiesis in red cell disorders, we analyzed the progression of
erythropoiesis in 3 anemic mouse models; 2 models with expected
normal progression of erythropoiesis and 1 model with ineffective
erythropoiesis. First, we examined erythropoiesis profiles in mice
with chronic hemolytic anemia because of deficiency of the red cell
cytoskeletal protein 4.1R14 and in WT mice with phlebotomy-
induced acute anemia. Because the spleen becomes erythropoietic
in mice under stress conditions, we examined the erythropoiesis
profiles of both bone marrow and spleen. Figure 2 top panel shows
the representative erythropoiesis profiles of bone marrow from WT,
4.1R/ and phlebotomized WT mice. Relative to WT bone
marrow, we demonstrate an increased proportion of nucleated
erythroblasts (IIIIIIIV) accompanied by a decreased propor-
tion of enucleated erythrocytes (VVI) in both 4.1R/ and
phlebotomized WT bone marrow. Quantitative analysis shown in
Table 2 demonstrated that in WT bone marrow (from 2 femurs and
2 tibias), the number of total nucleated erythroblasts is	 6.4 106,
whereas in 4.1R/ and in phlebotomized WT mouse bone the total
nucleated erythroblasts increased to 	 11.3  106 and
	 10.7 106, respectively. These findings demonstrate the in-
creased erythropoietic activity of bone marrow under stress condi-
tions. Of note, within the nucleated erythroblast population, the
Pro, Baso, Poly, and Ortho maintain the 1:2:4:8 ratio (Table 1),
confirming a normal progression of erythropoiesis in bone marrow
under erythropoietic stress. Figure 2 bottom panel shows the
representative erythropoiesis profiles of spleen from WT, 4.1R/,
and phlebotomized WT mice. Although few erythroblasts are
present in the WT spleens, significantly increased numbers of
erythroblasts can be found in the spleens of both 4.1R/ and
phlebotomy-induced anemic WT mice because of stress erythropoi-
esis in the spleen. Quantitative analysis showed that in WT spleen,
there were only 0.7 106 nucleated erythroblasts. In marked
contrast, in the 4.1R/ and phlebotomy-induced anemic WT
mouse spleens, the nucleated erythroblasts increased to 66.5 106
and 73.1 106, respectively (Table 2). Moreover, similar to bone
marrow, within the nucleated erythroblast population, the Pro,
Baso, Poly, and Ortho erythroblasts also followed the 1:2:4:8 ratio
(Table 1), demonstrating the normal progression of erythropoiesis
in the spleen as in the bone marrow in these 2 anemic models with
chronic and acute anemia.
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Altered erythropoiesis in the bone marrow and spleen of
Hbbth1/th1 mice and normalization after transferrin therapy
-thalassemia is characterized by ineffective erythropoiesis in
which erythroid expansion does not fully compensate the ane-
mia.18,19 However, it remains largely unclear at which stage of
erythropoiesis these alterations occur in -thalassemic mice. To
address this, we quantified in vivo erythropoiesis of both bone
marrow and spleen in Hbbth1/th1 mice. Figure 3A top and bottom
panels show the representative erythropoiesis profiles of bone
marrow and spleen from WT, PBS-injected Hbbth1/th1 mice, and
transferrin-injected Hbbth1/th1 mice. Similar to 4.1R/ and
phlebotomy-induced anemic mouse models, there is an expansion
of erythropoiesis in the bone marrow as well as spleen of Hbbth1/th1
mice. In PBS-treated Hbbth1/th1 mouse bone marrow, the nucleated
erythroblasts increased to 16.5 106 (from 6.4 106 in WT bone
marrow). Interestingly, in transferrin-treated Hbbth1/th1 mouse bone
marrow, the total number of nucleated erythroblasts is normal. The
expansion of erythropoiesis in PBS-treated Hbbth1/th1 mouse spleen
is even more dramatic as there is a 100-fold increase in nucleated
erythroblasts (from 0.7 106 in WT to 90  106 in PBS-treated
Hbbth1/th1). However, different from 4.1R/ and phlebotomized
WT bone marrow and spleen (both of which exhibited normal
progression of terminal erythroid differentiation) quantitative anal-
ysis revealed a decrease in the percentage of Pro and dispropor-
tional ratio of Pro to Baso erythroblasts in Hbbth1/th1. As shown in
Table 1, although Pro account for 6% to 7% of total nucleated
Figure 1. Flow cytometric analysis and isolation of erythroblasts of wild-type mice bone marrow cells. (A) Plot of FSC versus SSC of all the cells. (B) Plot of 7AAD
versus SSC of all the cells. (C) Plot of CD45CD11bGR1 versus SSC of all the cells. (D) Histogram of TER119 of CD45CD11bGR1 cells. (E) Plot of CD44 versus TER119 of
the TER119 positive cells without gating. (F) Plot of CD44 versus TER119 of the TER119 positive cells with the gating on CD44hiTERlow population I. (G) Plot of CD44 versus FSC of the
TER119 positive cells, showing naturally occurring clusters. (H) Plot of CD44 versus FSC of the TER119 positive cells with gating the population II, III, IV, V and VI. (I) Representative
cytospin images of the sorted populations. (J) Histogram of FSC of distinct stage of erythroblasts. (K) Proportion of distinct stage of erythroblasts in bone marrow.
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erythroblasts in WT, as well as in the 2 anemic mouse models, they
only account for 4.4% in Hbbth1/th1 mice. Moreover, whereas the
ratio of Pro/Baso erythroblasts is 1:2 in WT and 2 anemic mouse
models, it increased to 1:3.5 in Hbbth1/th1 mice. Importantly, the
erythropoiesis profiles are normalized in transferrin-treated
Hbbth1/th1 mouse bone marrow (Table 1). Lastly, the elevated serum
soluble transferrin receptor 1 (sTfR1), representing the total
increased erythroid population in Hbbth1/th1 mice, is reversed in
transferrin-treated Hbbth1/th1 mice (Figure 3B). This later finding
justifies the use of PBS and transferrin-treated Hbbth1/th1 mice as a
model in which to assess aberrant erythropoiesis and its resolution.
Discussion
This study establishes a reliable method to quantify differentiating
mouse erythroblasts and to monitor terminal in vivo erythropoiesis.
Using this method, we are able to define stage-specific changes in
terminal erythroid differentiation in the bone marrow and spleen of
Hbbth1/th1 mice and their reversal after transferrin treatment, previ-
ously shown to ameliorate disease in Hbbth1/th1 mice.17
A flow cytometry-based assay using CD71 (sometimes in
conjunction with forward scatter) as a differentiation marker has
been extensively used to study murine erythropoiesis in vivo over
the past decade. Our analysis of more than 40 previous published
studies using CD71 as a marker reveal large variations in the ratio
of Pro:Baso:Poly:Ortho in normal WT bone marrow. For example,
Halupa et al reported percentages of Pro:Baso:Poly:Ortho as 1.1:
39.5: 4.1: 55.3 for WT mice,9 whereas Mukai and colleagues
reported percentages of 0.5: 30.1: 25.6: 9.3,10 and Diwan et al
reported as 2: 16: 2: 27.11 Similarly, our analysis of 10 previous
studies using CD71 in conjunction with forward scatter also reveals
large inconsistencies in the ratio of Pro:Baso:Poly:Ortho in normal
murine bone marrow.6,20-28 None of these studies were able to
Table 1. Quantitation of terminal erythroid differentiation in normal and anemic mouse models
Pro (%) Baso (%) Poly (%) Ortho (%)
WT (n  20)
Bone marrow 6.1  1.2 12.7  1.6 27.7  1.4 53.1  3.0
Spleen Very low level of erythropoiesis
4.1R KO (n  6)
Bone marrow 6.5  0.5 13.9  1.2 27.8  1.4 52.2  2.2
Spleen 5.5  1.0 12.7  1.7 27.7  1.8 54.2  2.7
Phlebotomy-induced anemia (n  6)
Bone marrow 6.9  1.1 14.3  1.3 28.4  2.0 52.0  3.5
Spleen 7.0  1.1 13.7  2.0 26.3  4.9 50.5  5.4
Hbbth1/th1 (PBS-treated, n  6)
Bone marrow 4.4  0.3* 15.5  1.5† 26.7  0.9 53.5  1.3
Spleen 4.7  1.1‡ 15.1  4.7§ 26.6  3.0 53.6  8.4
Hbbth1/th1 (transferrin-treated n  6)
Bone marrow 6.6  0.8 13.9  2.7 25.6  2.2 51.3  1.5
Spleen Very low level of erythropoiesis
The proportion of cells at each distinct stage of maturation is normalized based on total nucleated erythroblasts as 100%.
WT indicates wild-type.
*P 
 .0026 WT versus Hbbth1/th1 mice.
†P 
 .0023 WT versus Hbbth1/th1 mice.
‡P 
 .033 WT versus Hbbth1/th1 mice.
§P 
 .042 WT versus Hbbth1/th1 mice.
Figure 2. Representative erythropoiesis profiles of
bone marrow and spleen of 4.1R/ and phlebotomy-
induced mice. (Top panel) Representative erythropoi-
esis profiles of bone marrow. Note that there is an
increased proportion of nucleated erythroblasts
(IIIIIIIV) which is accompanied by a decreased
proportion of enucleated erythrocytes (VVI) in both
4.1R/ and phlebotomy-induced WT bone marrow com-
pared with WT bone marrow. (Bottom panel) Representa-
tive erythropoiesis profiles of spleen. Note that there are
very few erythroblasts in WT spleen but a large propor-
tion of nucleated erythroblasts in the spleens of both
4.1R/ and phlebotomy-induced WT anemic mice.
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document physiologic progression of terminal erythroid differentia-
tion in normal bone marrow. As such, the reported stage-specific
erythropoietic defects in various genetically engineered mice using
CD71 as a marker is highly problematic.
The novel method presented in this paper enables successful
in vivo quantitation of mouse terminal erythroid differentiation.
This success is largely attributed to clear separation of all
terminally differentiating erythroid cells, namely Pro, Baso, Poly,
Ortho erythroblasts, reticulocytes, and mature red blood cells,
using surface markers TER119 and CD44 in conjunction with
forward scatter. The failure of previous studies to quantify this
process using Ter119 and CD71 is because of the fact that in
contrast to CD44 expression that decreases progressively after each
cell division, there is little change in CD71 expression after each
cell division.13 In the original study using CD71 and TER119 as
markers for erythroid cell differentiation, the authors defined
4 regions I, II, III, and IV. They indicated that these regions are
enriched in Pro, Baso, Poly, and Ortho erythroblasts, respectively.5
Even after the addition of FSC as an additional marker, the defined
erythroblast populations (namely Pro-E, Ery-A, Ery-B, and Ery-C)
did not improve the discrimination between different stages.
Our findings also provide new insights into the splenic and bone
marrow responses to stress erythropoiesis. In mice, although it is
well accepted that the spleen becomes erythropoietic under stress
conditions, it has been unclear to what extent the bone marrow can
increase its erythroid output in response to stress. Furthermore, the
extent of the splenic response has not been carefully defined. Our
findings demonstrate that the total number of erythroblasts (which
reflects the erythropoietic activity) is increased 	 2-fold in the
bone marrows of all 3 anemic mice: 1 acute (phlebotomy-induced)
and 2 chronic anemic mouse models (4.1R/ and Hbbth1/th1),
implying that murine bone marrow can double its erythropoietic
activity in response to anemic stress. In marked contrast, under
both chronic and acute stress conditions the erythropoietic response
of the spleen increases much more dramatically (	 100-fold), with
the spleen transforming from an essentially non-erythropoietic
organ in the adult mice to an active erythropoietic tissue.
The major observed effect of erythropoiesis in Hbbth1/th1 mice is
a disturbed proportion of proerythroblasts versus basophilic eryth-
roblasts in bone marrow and spleen samples. During normal
erythropoiesis, iron is progressively incorporated into hemoglobin
and thus safely sequestered, avoiding potential redox reactive
damage. Thus, early stage erythroid precursors are exposed to high
iron concentrations, as evidenced by CD71-positive early stage
erythroid precursors, with later stages accumulating hemoglobin as
it is progressively synthesized and thus reducing total cellular iron.
In -thalassemia, an additional progressive accumulation of un-
paired  globin occurs. Furthermore, systemic iron overload, as
occurs in -thalassemia, may result in the formation of labile iron
Figure 3. Altered terminal erythroid differentiation of
Hbbth1/th1 mice and normalization after thansferrin
therapy. (A) Representative erythropoiesis profiles of
bone marrow and spleen of Hbbth1/th1 mice. (Top panel)
The representative erythropoiesis profiles of bone mar-
row. A decrease in fraction I (proerythroblast) and fraction
VI (mature red cells) is clearly seen in PBS-treated
thalassemia bone marrow and is restored in transferrin-
treated bone marrow. (Bottom panel) Representative
erythropoiesis profiles of spleen. There are very few
erythroblasts in WT spleen, but the spleen of thalassemia
mouse is highly erythropoietic and is restored in
transferrin-treated spleen. (B) Western blot revealed an
increase in soluble serum TfR1 in Hbbth1/th1 relative to WT
mice and is normalized after transferrin treatment.
Table 2. Total number of erythroblasts in bone marrow and spleen






 20) 6.4  0.9 0.7  0.1
4.1R KO (n 
 6) 11.3  1.1* 66.5  5.4†
Phlebotomy induced anemia (n 
 6) 10.9  1.2* 73.1  3.0†
Hbbth1/th1 (PBS-treated, n 
 6) 16.5  0.7† 90.4  6.3†
Hbbth1/th1 (transferrin-treated, n 
 6) 6.4  1.1 0.8  0.1
Bone marrow cells are from 2 tibia and 2 femurs.
*P  .001.
†P  .0001.
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and negatively affect cells with high iron uptake in addition to
unpaired  globin membrane precipitation in later stages. Improved
erythropoiesis after iron chelation is evident in transfusion-
requiring anemias.29 Taken together, the increased systemic iron,
disordered hemoglobin synthesis, and high iron uptake support the
particular sensitivity of early erythroid precursors to labile iron-
induced damage in -thalassemia. We hypothesize that once
erythroid precursors survive a critically sensitive point in matura-
tion, cell division proceeds relatively unimpeded. Our data suggest
that ineffective erythropoiesis in-thalassemia results from dysfunc-
tional differentiation because of excess iron and unpaired  globin
chains and is reversed by exogenous transferrin; this finding is also
supported by normalized serum sTfR1, a typical marker reflecting
degree of defective or iron-deficient erythropoiesis.30,31
This newly established method is broadly applicable in the
study of altered murine erythropoiesis. Moreover, its use will
probalby provide important leads for mechanistic studies defining
stage-specific defects in erythroid maturation in inherited and
acquired red cell disorders.
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